http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EA-201201225-A1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-137 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-06 |
| filingDate | 2012-10-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2014-04-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EA-201201225-A1 |
| titleOfInvention | SOLID MEDICINE FORM, possessing an anorexigenic action (OPTIONS) |
| abstract | The invention relates to the pharmaceutical industry and medicine and can be used in the creation and use of solid dosage forms for the treatment and / or prevention of obesity. The objective of the invention is the creation of an effective solid dosage form using sibutramine hydrochloride monohydrate with anorexigenic action. The problem is solved by introducing into the solid dosage form additional minerals, as well as through the use of carbon isotopes and nitrogen. The technical results of the invention are to increase the therapeutic effect (decrease in body weight or decrease in the rate of weight gain) while maintaining the duration of action without increasing the concentration of sibutramine hydrochloride monohydrate in the treatment and / or prevention of obesity; reducing the time of onset of therapeutic effect. |
| priorityDate | 2012-10-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 19.